Head-To-Head Contrast: Traws Pharma (TRAW) vs. Its Competitors

Traws Pharma (NASDAQ:TRAW) is one of 1,033 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Traws Pharma to similar businesses based on the strength of its risk, analyst recommendations, institutional ownership, profitability, earnings, valuation and dividends.

Profitability

This table compares Traws Pharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Traws Pharma	-60,641.14%	-144.95%	-633.17%
Traws Pharma Competitors	-3,618.99%	-298.36%	-32.36%

Earnings and Valuation

This table compares Traws Pharma and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Traws Pharma	$230,000.00	-$18.95 million	-8.08
Traws Pharma Competitors	$2.11 billion	$148.11 million	-4.78

Traws Pharma’s peers have higher revenue and earnings than Traws Pharma. Traws Pharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Traws Pharma has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Traws Pharma’s peers have a beta of 1.01, suggesting that their average share price is 1% more volatile than the S&P 500.

Insider and Institutional Ownership

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 44.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 3.3% of Traws Pharma shares are held by company insiders. Comparatively, 14.0% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Traws Pharma and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	0	0	0	0	N/A
Traws Pharma Competitors	7213	20142	47191	1100	2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 63.27%. Given Traws Pharma’s peers higher possible upside, analysts clearly believe Traws Pharma has less favorable growth aspects than its peers.

Summary

Traws Pharma peers beat Traws Pharma on 8 of the 10 factors compared.

Traws Pharma Company Profile

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.